Results 11 to 20 of about 30,393,220 (286)
Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib [PDF]
Clinical, Cosmetic and Investigational DermatologyYingzhi Luo,1,* Jian Wu,2,* Xingyun Zhao,1,* Ping Yang,1 Yunmi Qiu,1 Liming Wu,1 Jianbo Zhong1 1Department of Dermatology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang ...
Luo Y +6 more
doaj +4 more sources
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011 Review on JAK1 (Janus kinase 1), with data on DNA, on the protein encoded, and where the gene is implicated.
Knoops, L, Hornakova, T, Renauld, JC
openaire +4 more sources
Janus kinase inhibitors: jackpot or potluck?
Oncology Reviews, 2012 The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat +1 more
doaj +2 more sources
Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells. [PDF]
J Cell Mol Med, 2021 AbstractProstate cancer (PCa) is the second most common malignancy and is the fifth leading cause of cancer mortality among men globally. Docetaxel‐based therapy remains the first‐line treatment for metastatic castration‐resistant prostate cancer. However, dose‐limiting toxicity including neutropenia, myelosuppression and neurotoxicity is the major ...
Nalairndran G +8 more
europepmc +5 more sources
IL-17A Damages the Blood–Retinal Barrier through Activating the Janus Kinase 1 Pathway [PDF]
Biomedicines, 2021 Blood–retinal barrier (BRB) dysfunction underlies macular oedema in many sight-threatening conditions, including diabetic macular oedema, neovascular age-related macular degeneration and uveoretinitis.
Eimear M. Byrne +5 more
doaj +2 more sources
Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1. [PDF]
Cancers (Basel), 2019 Janus kinases (JAKs) are found constitutively associated with cytokine receptors and are present in an inactive state prior to cytokine exposure. Activating mutations of JAKs are causative for a number of leukemias, lymphomas, and myeloproliferative diseases.
Liau NPD +6 more
europepmc +5 more sources
miR-20a-5p inhibits endometrial cancer progression by targeting janus kinase 1. [PDF]
Oncol Lett, 2021 Endometrial cancer (EC) is a multi-factorial disease of which pathogenesis has not been fully elucidated. The function and underlying mechanism of microRNA-20a-5p (miR-20a-5p) in EC remain poorly understood. The present study aimed to analyze the association between miR-20a-5p expression and the clinicopathological characteristics of patients with EC ...
He Y, Ma H, Wang J, Kang Y, Xue Q.
europepmc +4 more sources
Successful treatment of pyoderma gangrenosum with Janus kinase 1/2 inhibition
JEADV Clinical Practice, 2022 Pyoderma gangrenosum (PG) is a rare, autoinflammatory disease leading to painful, hard‐to‐treat ulcers. Besides systemic glucocorticoids, a plethora of classic immunosuppressants, biologics and small molecules have been reported to improve PG disease ...
Sebastian Sitaru +2 more
doaj +2 more sources
Nature Communications, 2021 Increased risk of premature cardiovascular disease in systemic lupus erythematosus (SLE) is not well understood, but in animal models, the Janus kinase inhibitor tofacitinib improves related phenotypes.
Sarfaraz A. Hasni +38 more
doaj +2 more sources
A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs
Molecular & Cellular Oncology, 2021 While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder +2 more
doaj +1 more source